Address: Via Giovanni da Procida 11, 20149 Milano,Italy
Tel: +39 02 34565306
Web: http://assobiotec.federchimica.it/
Set up in October 1986 within the Italian Federation of the Chemical Industry (Federchimica), Assobiotec is the Italian Association for the Development of Biotechnology, representing more than 120 companies and science & technology parks operating in Italy and involved in various biotech-related fields – pharmaceuticals, diagnostics, agro-food, fine chemicals, environment, processing industry and equipment. They include emerging biotech companies and small to medium enterprises, as well as the biotech divisions of large organisations.
Assobiotec is co-founder member of EuropaBio, the European Association for Bioindustries, created in 1996.
Assobiotec provides entrepreneurial support to Italian and EU biotech developments and is the landmark for Italian companies involved in production and marketing of products derived from biotech applications.
Assobiotec focuses its main attention on:
regulatory issues affecting production, marketing and use of biotechnology products and their standards harmonisation;
fiscal and financial policies aimed at motivating industrial innovation;
R&D, education and training projects and programmes.
Assobiotec’s policy is mainly dealing with:
monitoring legislation in the regulatory area;
representing Italian bioindustry at National and international level;
providing a regular forum for the exchange of information and initiatives of entrepreneurial relevance;
taking active part to the reviewing process concerning the rules on industrial property.
Assobiotec’s activities include:
close interaction with National and international trade organisations dealing with biotechnology;
regular contacts with Universities, fostering collaboration between academia and industry in research and education;
information services on commercial biotech applications, on patents and on R&D programmes implementation.
Assobiotec’s Leonardo Vingiani introduces the key trends shaping the Italian biotech ecosystem today, the steps that the country’s government have taken to foster life sciences innovation, and the areas in…
Leonardo Vingiani, Director of Assobiotec, discusses how the country’s biotech industry has evolved since 2009, what areas still need improving and the enormous progress which has been made in unlocking…
Biotechnologies have a significant role to play bringing Italy towards a more knowledge-based economy. What is the economic contribution of the sector today? According to the last Blossom Associati-Assobiotec report…
The grants and loans allocated by the European Union’s Recovery and Resilience Facility (RRF), a large part of which have been assigned to healthcare, set out to mitigate the economic…
After former CEO Pierluigi Antonelli abruptly announced his departure last month, the Italian mid-cap has signed on former Gilead leader, Jacopo Andreose, as its new chief executive. [I am]…
Angelini Pharma CEO Pierluigi Antonelli has announced that he is leaving his position with immediate effect, posing the question of what comes next for the leading Italian mid-cap. Antonelli,…
The electoral victory of the centre-right coalition in Italy should see far-right firebrand Giorgia Meloni replace former European Central Bank President Mario Draghi as Prime Minister at the end of…
Digitalisation has become a buzz word in in the global life sciences sector. In Italy, digital transformation has taken on special significance as one of the principal goals encompassed in…
The Italian system requires drug companies to go through approvals at a national level with the Italian Medicines Agency (AIFA), only to then confront the country’s 21 regional authorities who…
Historically, SIFI has been a modest local player focused on ophthalmic products, but in recent years the company has set some ambitious goals for itself—becoming a leading force in European…
Seasoned executive Pierluigi Antonelli went from a career in big pharma to Angelini Pharma, a midsized Italian company that has been undergoing major transformation. He shares the motivation behind the…
Collectively representing almost 400 companies operating in Italy, Farmindustria, Egualia (formerly Assogenerici) and Assobiotec respectively promote the interests of innovative pharmaceutical companies—both foreign and Italian-owned— the generics, biosimilars and value-added…
As the European Union’s largest beneficiary of the Next Generation EU (NGEU) package, aimed at boosting the EU’s economy following the COVID-19 pandemic, Italy will receive some EUR 235 billion…
While Italy’s biotech landscape is generally held to be somewhat immature in comparison to more established markets such as Germany, France or the UK, that does not imply a deficit…
Dr Nicola Normanno, the Director of the Translational Research Department of one of Italy’s national cancer institutes, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, and president of the Italian Cancer…
See our Cookie Privacy Policy Here